Brooklyn Immunotherapeutics Inc
Change company Symbol lookup
Select an option...
BTX Brooklyn Immunotherapeutics Inc
SBCF Seacoast Banking Corporation of Florida
MSSAU Metal Sky Star Acquisition Corp
SDGR Schrodinger Inc
GPC Genuine Parts Co
VENA Venus Acquisition Corp
VECO Veeco Instruments Inc
IGTAU Inception Growth Acquisition Ltd
BAC-K Bank of America Corp
FAX abrdn Asia-Pacific Income Fund Inc

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology |
Company profile

Brooklyn ImmunoTherapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cytokine-based therapies for treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Its lead product candidate, IRX-2, is a cytokine therapy, to treat patients with head and neck cancer. IRX-2 is a mixed, human-derived cytokine product with multiple active constituents including Interleukin-2 (IL2) and other key cytokines, which restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. The Company also has multiple cell and gene-editing therapies in preclinical development for various indications, including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. Its subsidiaries include Brooklyn ImmunoTherapeutics LLC, Novellus, Inc. and Novellus Therapeutics, Ltd.

Closing Price
Day's Change
-0.0319 (-12.17%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Coronavirus tally: Biden administration will halt boosters for under-50s until new ones are ready in September to attack omicron

6:10 am ET July 29, 2022 (MarketWatch)

The Biden administration has decided against offering COVID boosters to people under 50 for now, preferring to wait until retooled Pfizer (PFE) and Moderna (MRNA) shots become available in September that could perform better against the omicron BA.5 subvariant, the New York Times reported Thursday The reasoning is that it'll be worth it for those under 50 to wait slightly longer for the improved booster, rather than expand eligibility now with the older shot. While the older version is still highly effective at preventing serious symptoms and death, the new, omicron-specific boosters are expected to provide better defense against BA.5, though data on that is still preliminary. The news comes as the daily average for new U.S. cases remains close to 130,000 a day, but not all data are being captured as many people are testing at home. The average stoold at 127,022 on Thursday, according to a New York Times tracker, down 2% from two weeks ago. The daily average for hospitalizations rose to 43,696 up 10% in two weeks. The daily average for deaths is up 4% to 438. Globally, the confirmed case tally rose above 574.8 million on Thursday, according to data aggregated by Johns Hopkins, while the death toll is above 6.39 million with the U.S. leading the world with 91.1 million cases and 1,029,270 deaths.

-Ciara Linnane


(END) Dow Jones Newswires

July 29, 2022 06:10 ET (10:10 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.